文献速递肾小球疾病

原发性膜性肾病的临床解读

Primary Membranous Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-05-26

本文综述原发性膜性肾病(PMN)的发病机制与诊疗。约70%患者有抗PLA2R抗体,3%-5%有抗THSD7A抗体。未治疗者约三分之一自发缓解,三分之一10年内进展至ESRD。所有患者应接受支持治疗,高危者考虑免疫抑制。

要点

  • PMN诊断需检测抗PLA2R抗体,阴性者考虑抗THSD7A或肾活检。
  • 所有PMN患者从诊断起应接受支持治疗以减少蛋白尿。
  • 抗PLA2R/THSD7A升高且蛋白尿>3.5g/d者考虑免疫抑制治疗。

核心结论

  • PMN是成人非糖尿病白种人特发性肾病综合征最常见病因。
  • 约80%病例为肾脏局限的原发性膜性肾病(PMN)。
  • 未治疗者约三分之一自发缓解,三分之一10年进展至ESRD。
  • 经适当管理,10年内进展至ESRD者仅10%或更少。

研究设计与样本

  • 本文为综述,聚焦原发性膜性肾病(PMN),不涉及继发性膜性肾病。

主要发现

  • 约70% PMN患者有循环IgG4抗PLA2R抗体。
  • 约15%患者肾活检PLA2R染色阳性但血清抗体阴性,提示近期免疫活动。
  • 3%-5%患者有血清抗THSD7A抗体。
  • 剩余10%无已知抗体或抗原,可能继发于未鉴定的抗足细胞抗体。
  • 80% PMN患者表现为肾病综合征,20%为非肾病性蛋白尿。

关键数值与推荐

  • 诊断时抗PLA2R/THSD7A升高且蛋白尿>3.5 g/d者考虑免疫抑制治疗。
  • 支持治疗6个月后蛋白尿未降至<3.5 g或出现肾病综合征并发症者考虑免疫抑制治疗。
  • 公认的免疫抑制方案包括激素/环磷酰胺、钙调磷酸酶抑制剂和B细胞清除治疗。

临床怎么用

  • 所有PMN患者从诊断起应接受支持治疗以最小化蛋白排泄。
  • 根据抗PLA2R/THSD7A水平和蛋白尿程度分层决定是否启动免疫抑制。
  • 免疫学缓解后蛋白尿可能持续数月,需监测。

局限性

  • 本文为综述,未报告原始研究样本量、P值等具体数据。
  • 约10% PMN患者抗体未明,机制待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Membranous nephropathy (MN) is a unique glomerular lesion that is the most common cause of idiopathic nephrotic syndrome in nondiabetic white adults. About 80% of cases are renal limited (primary MN, PMN) and 20% are associated with other systemic diseases or exposures (secondary MN). This review focuses only on PMN. Most cases of PMN have circulating IgG4 autoantibody to the podocyte membrane antigen PLA2R (70%), biopsy evidence PLA2R staining indicating recent immunologic disease activity despite negative serum antibody levels (15%), or serum anti-THSD7A (3%-5%). The remaining 10% without demonstrable anti-PLA2R/THSd7A antibody or antigen likely have PMN probably secondary to a different, still unidentified, anti-podocyte antibody. Considerable clinical and experimental data now suggests these antibodies are pathogenic. Clinically, 80% of patients with PMN present with nephrotic syndrome and 20% with non-nephrotic proteinuria. Untreated, about one third undergo spontaneous remission, especially those with absent or low anti-PLA2R levels, one-third progress to ESRD over 10 years, and the remainder develop nonprogressive CKD. Proteinuria can persist for months after circulating anti-PLA2R/THSD7A antibody is no longer detectable (immunologic remission). All patients with PMN should be treated with supportive care from the time of diagnosis to minimize protein excretion. Patients with elevated anti-PLA2R/THSD7A levels and proteinuria >3.5 g/d at diagnosis, and those who fail to reduce proteinuria to <3.5 g after 6 months of supportive care or have complications of nephrotic syndrome, should be considered for immunosuppressive therapy. Accepted regimens include steroids/cyclophosphamide, calcineurin inhibitors, and B cell depletion. With proper management, only 10% or less will develop ESRD over the subsequent 10 years.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017. PMID: 28550082. doi:10.2215/CJN.11761116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。